ARD-353 [4-((2R,5S)-4-(R)-(4-diethylcarbamoylphenyl)(3-hydroxyphenyl) methyl)-2,5-dimethylpiperazin-1-ylmethylbenzoic acid], a novel nonpeptide δ receptor agonist, reduces myocardial infarct size without central effects

Journal of Pharmacology and Experimental Therapeutics

Volumn 316, Issue 1, 2006, Pages 423-430

  Watson, Michael J ^a   Holt, Jonathon D S ^a   O'Neill, Scott J ^a   Wei, Ke ^a   Pendergast, William ^a   Gross, Garrett J ^b   Gengo, Peter J ^c   Chang, Kwen Jen ^a  

^a Enhance Biotech Inc   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c ALZA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[(4 DIETHYLCARBAMOYLPHENYL)(3 HYDROXYPHENYL)METHYL] 2,5 DIMETHYLPIPERAZIN 1 YLMETHYL]BENZOIC ACID; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N,N DIETHYLBENZAMIDE; 7 BENZYLIDENENALTREXONE; ARD 353; BENZOIC ACID DERIVATIVE; DELTA OPIATE RECEPTOR AGONIST; ISOPRENALINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CONVULSION; DRUG EFFECT; HEART INFARCTION; HEART INFARCTION SIZE; HEART PROTECTION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE; STATISTICAL SIGNIFICANCE; VAS DEFERENS;

ANIMALS; BENZOIC ACIDS; BENZYLIDENE COMPOUNDS; BINDING, COMPETITIVE; CARDIOTONIC AGENTS; CATALEPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMODYNAMIC PROCESSES; MALE; MICE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NALTREXONE; PIPERAZINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; REFLEX; SEIZURES;

EID: 29244490897     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.092742     Document Type: Article

References (35)

1. Bachelard H and Pitre M (1995) Regional haemodynamic effects of mu-, delta- and kappa-opioid agonists microinjected into the hypothalamic paraventricular nuclei of conscious, unrestrained rats. Br J Pharmacol 115:613-621.
2. Baxter GF, Goma FM, and Yellon DM (1997) Characterization of the infarct-limiting effect of delayed preconditioning: time course and dose-dependency studies in rabbit myocardium. Basic Res Cardiol 92:159-167.
3. Baxter GF, Marber MS, Patel VC, and Yellon DM (1994) Adenosine receptor involvement in a delayed phase of myocardial protection 24 hours after ischemic preconditioning. Circulation 90:2993-3000.
4. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
5. Broom DC, Jutkiewicz EM, Rice KC, Traynor JR, and Woods JH (2002a) Behavioral effects of delta-opioid receptor agonists: potential antidepressants. Jpn J Pharmacol 90:1-6.
6. Broom DC, Nitsche JF, Pintar JE, Rice KC, Woods JH, and Traynor JR (2002b) Comparison of receptor mechanisms and efficacy requirements for delta-agonistinduced convulsive activity and antinociception in mice. J Pharmacol Exp Ther 303:723-729.
7. + exchange. Basic Res Cardiol 91:203-209.
8. Cavun SM, Goktalay G, and Millington WR (2004) The hypotension evoked by visceral nociception is mediated by delta opioid receptors in the periaquaductal gay. Brain Res 1019:237-245.
9. Chang KJ, Rigdon GC, Howard JL, and McNutt RW (1993) A novel, potent and selective nonpeptidic delta opioid receptor agonist BW373U86. J Pharmacol Exp Ther 267:852-857.
10. Comer SD, Hoenicke EM, Sable AI, McNutt RW, Chang KJ, De Costa BR, Mosberg HI, and Woods JH (1993) Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice. J Pharmacol Exp Ther 267:888-895.
11. Farias M, Jackson K, Yoshishige D, and Caffrey JL (2003) Bimodal δ-opioid receptors regulate vagal bradycardia in canine sinoatrial node. Am J Phyiol Heart Circ Physiol 285:H1332-H1339.
12. Fryer RM, Hsu AK, Eells JT, Nagase H, and Gross GJ (1999) Opioid-induced second window of cardioprotection: potential role of mitochondrial KATP channels. Circ Res 84:846-851.
13. Gross ER, Peart JN, Hsu AK, Auchampach JA, and Gross GJ (2005) Extending the cardioprotective window using a novel delta-opioid agonist fentanyl isothiocyanate via the PI3-kinase pathway. Am J Physiol 288:H2744-H2749.
14. Gross GJ and Auchampach JA (1992) Role of ATP dependent potassium channels in myocardial ischaemia. Cardiovasc Res 26:1011-1016.
15. Holaday JW (1983) Cardiovascular effects of endogenous opiate systems. Annu Rev Pharmacol Toxicol 23:541-594.
16. Keay KA, Crowfoot LJ, Floyd NS, Henderson LA, Christie MJ, and Bandler R (1997) Cardiovascular effects of microinjections of opioid agonists into the "depressor region" of the ventrolateral periaquaductal gray region. Brain Res 762:61-71.
17. Knapp RJ, Landsman R, Waite S, Malatynska E, Varga E, Haq W, Hruby VJ, Roeske WR, Nagase H, and Yamamura HI (1995) Properties of TAN-67, a nonpeptidic delta-opioid receptor agonist, at cloned human delta- and mu-opioid receptors. Eur J Pharmacol 291:129-134.
18. Lasley RD and Mentzer RM Jr (1993) Pertussis toxin blocks adenosine A1 receptor mediated protection of the ischemic rat heart. J Mol Cell Cardiol 25:815-821.
19. Liu GS, Thornton J, Van Winkle DM, Stanley AW, Olsson RA, and Downey JM (1991) Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 84:350-356.
20. Murry CE, Jennings RB, and Reimer KA (1986) Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74:1124-1136.
21. Patel HH, Hsu A, Moore J, and Gross GJ (2001) BW373U86, a delta opioid agonist, partially mediates delayed cardioprotection via a free radical mechanism that is independent of opioid receptor stimulation. J Mol Cell Cardiol 33:1455-1465.
22. + exchange in ischemia-reperfusion. Basic Res Cardiol 91:191-202.
23. + exchange inhibitor reduces infarct size in pigs. Cardiovasc Res 30:945-951.
24. Schultz JE, Hsu AK, and Gross GJ (1998) Ischemic preconditioning in the intact rat heart is mediated by delta1- but not mu- or kappa-opioid receptors. Circulation 97:1282-1289.
25. Schultz JJ, Hsu AK, and Gross GJ (1997a) Ischemic preconditioning and morphineinduced cardioprotection involve the delta (delta)-opioid receptor in the intact rat heart. J Mol Cell Cardiol 29:2187-2195.
26. Schultz JJ, Hsu AK, and Gross GJ (1997b) Ischemic preconditioning is mediated by a peripheral opioid receptor mechanism in the intact rat heart. J Mol Cell Cardiol 29:1355-1362.
27. Thornton JD, Liu GS, and Downey JM (1993) Pretreatment with pertussis toxin blocks the protective effects of preconditioning: evidence for a G-protein mechanism. J Mol Cell Cardiol 25:311-320.
28. Tomai F, Crea F, Gaspardone A, Versaci F, Ghini AS, Ferri C, Desideri G, Chiariello L, and Gioffre PA (1999) Effects of naloxone on myocardial ischemic preconditioning in humans. J Am Coll Cardiol 33:1863-1869.
29. Wong TM, Lee AY, and Tai KK (1990) Effects of drugs interacting with opioid receptors during normal perfusion or ischemia and reperfusion in the isolated rat heart: an attempt to identify cardiac opioid receptor subtype(s) involved in arrhythmogenesis. J Mol Cell Cardiol 22:1167-1175.
30. Xenopoulos NP, Leesar M, and Bolli R (1998) Morphine mimics ischemic preconditioning in human myocardium during PTCA. J Am Coll Cardiol 65:65A
31. Yamashita N, Hoshida S, Taniguchi N, Kuzuya T, and Hori M (1998) A "second window of protection" occurs 24 h after ischemic preconditioning in the rat heart. J Mol Cell Cardiol 30:1181-1189.
32. Yao Z and Gross GJ (1993a) Acetylcholine mimics ischemic preconditioning via a glibenclamide-sensitive mechanism in dogs. Am J Physiol 264:H2221-H2225.
33. + channel in mediating the effects of acetylcholine to mimic preconditioning in dogs. Circ Res 73:1193-1201.
34. Yellon DM and Baxter GF (1995) A "second window of protection" or delayed preconditioning phenomenon: future horizons for myocardial protection? J Mol Cell Cardiol 27:1023-1034.
35. Ytrehus K, Liu Y, and Downey JM (1994) Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol 266:H1145-H1152.